|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| BIOGRAPHICAL SKETCH | | | | |
|  | | | | |
| NAME  Argyrios Tzouvelekis | | POSITION TITLE  Postdoctoral Associate | | |
| EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)* | | | | |
| INSTITUTION AND LOCATION | DEGREE  *(if applicable)* | | YEAR(s) | FIELD OF STUDY |
| University of Crete School of Medicine, Greece | MD | | 2003 | Medicine |
| Democritus University of Thrace, Medical School, Greece | PhD | | 2008 | Role of Hypoxia Inducible Factor 1a in the pathogenesis of Idiopathic Pulmonary Fibrosis |
| Medical School, Democritus University of Thrace and Medical School, University of Crete, Greece | MSc | | 2011 | Clinical Pharmacology and Therapeutics |

**A. Personal Statement**

Dr. Argyrios Tzouvelekis’s research focus is the mechanisms of pulmonary fibrosis, centering on the identification of prognostic biomarkers and the delineation of novel therapeutic targets, using advanced methodological tools, including microarray and miRNA platforms, nCounter (Nanostring) technology and animal models of lung fibrosis (ie bleomycin-induced). Dr. Tzouvelekis’s specialties are focused on the implementation of pioneering research technologies, such as microarrays, as well as the application of novel therapeutic interventions including stem cells. His main areas of expertise are Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases. He currently enumerates **67 publications** in peer-reviewed scientific journals (with an overall of **1018 citations** and a total **H-index=19**), more than 60 presentations and lectures in national and international conferences and **20 grants** and honors, including European Respiratory Society **a) Long Term Fellowship and b) Young Scientist Sponsorship and c) American Lung Association Senior Research Training Fellowship, d) an ERS/Marie Skłodowska-Curie Postdoctoral Research Fellowship.** Dr. Tzouvelekis was the principal investigator of the first worldwide stem cell clinical trial in patients with Idiopathic Pulmonary Fibrosis that was recently published (2013) in *Journal of Translational Medicine*. He has also participated as sub-investigator in several multicenter pharmaceutical clinical trials conducted in the Department of Pneumonology, Medical School, at the Democritus University of Thrace. **Dr Tzouvelekis is also the inventor of a therapeutic patent entitled “Inhaled or aerosolized delivery of thyroid hormone to the lung as a novel therapeutic agent in fibrotic lung diseases” OCR#6368 (the “Invention”), disclosed to Yale University**. His research interests mainly focus on understanding the role of phosphatases and thyroid hormone signaling in the pathogenesis of lung fibrosis. He was trained in major aspects of translational medicine, including genomics and proteomics, as well as in molecular and cellular fibroblast biology. He was privileged to be mentored by world experts in the field of Interstitial Lung Diseases including, Naftali Kaminski, Demosthenes Bouros, Ron du Bois and Athol Wells.

In 2003, he graduated from the School of Medicine, University of Crete, Greece. From 2004-2008, Dr. Tzouvelekis successfully completed his PhD studies with grade of “excellence” in the Medical School, Democritus University of Thrace. In 2004, he was granted with the European Respiratory Society Long Term Research Fellowship and worked up to October 2005 as a research fellow in the Interstitial Lung Disease Unit, Imperial College, Royal Brompton and Harefield Hospital, London, where he specialized in the genotypic analysis of patients with different forms of interstitial lung diseases. From 2007 to 2012, Dr. Tzouvelekis successfully completed with excellence his rotation in the Departments of Pneumonology, Internal and Critical Care Medicine, Medical School at Democritus University of Thrace, Greece. Throughout his rotation, Dr. Tzouvelekis performed over 500 flexible bronchoscopic and more than 50 rigid port thoracoscopic procedures. In July 2011, he extended his skills of expertise in the area of clinical pharmacology and he was granted with excellence, a master (MSc) of Clinical Pharmacology and Therapeutics. In 2012, he successfully took the exams and was awarded the HERMES European Respiratory Diplomat in recognition of his clinical skills and knowledge on a European level. He is a member of the Hellenic Thoracic, European Respiratory and the American Thoracic Society.

**B. Positions and Honors**

**Professional Experience**

Oct 2004 – Oct 2005 European Respiratory Society, Long Term Research Fellowship, Imperial College

Royal Brompton Hospital, London, UK

Dec 2007 – May 2012 Internal Medicine Residency and Fellowship in Pulmonary, Critical Care and Sleep

Medicine; Department of Pneumonology, Internal and Critical Care Medicine, Medical

School, Democritus University of Thrace, Greece.

Mar 2009 – Jul 2011 Master (MSc) of Clinical Pharmacology and Therapeutics, Medical School, Democritus

University of Thrace and Medical School, University of Crete, Greece

May 2012– Aug 2012 Academic Visitor, Laboratory of Immunogenomics and Immunoproteomics, Faculty

Of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

Sep 2012 HERMES European Respiratory Diplomat

Sep 2012 – May 2013 Compulsory Military Service, Greece

Oct 2013 – present Postdoctoral Associate, Yale University School of Medicine, and Department of Internal

Medicine, Section of Pulmonary, Critical Care & Sleep Medicine, New Haven CT

**Honors and Awards**

Oct 2004 – Oct 2005 Long Term Research Fellowship, European Respiratory Society, Imperial College Royal Brompton Hospital, London

Dec 2005 1st Award GlaxoSmithKline annual research grant, Title of project: “The role of angiogenesis in the pathogenesis of Idiopathic Interstitial Pneumonias”

Dec 2006 Bursary for the 5th International Lung Science ERS Conference, Taormina, Sicily

Sep 2007 ERS young scientist sponsorship, ERS congress, Stockholm

May 2008 American Thoracic Society, Public Advisory Roundtable, Allergy, Immunology and Inflammation, Award. ATS congress, Toronto

Oct 2008 Top 5% special abstract award, ERS congress, Berlin

Nov 2008 1st Award GlaxoSmithKline Annual Research Grant, Title of project: “The coagulation cascade in the pathogenesis of fibrotic lung disease. Study of the role of Tissue Factor (TF) in different forms of pulmonary fibrosis.”

Nov 2011 1st Unrestricted grant by Hellenic Thoracic Society, Title of project: “Study of the role of the adipose derived stem cells-stromal vascular fraction (SVF) in the treatment and pathogenesis of lung fibrosis”

Aug 2013 Oral Presentation Award, Session 6. Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Conference, University of Vermont, Burlington, VT. “A prospective, nonrandomized no placebo controlled phase Ib clinical trial to study the safety of the adipose derived stem cells in patients with Idiopathic Pulmonary Fibrosis”

July 2015 American Lung Association Senior Research Training Fellowship, Title of Project: SHP-2 as a Novel Anti-Fibrotic Agent in IPF

**C. Publications:**

1) **Total Number of Publications:** 71 (67 PubMed)

2) **Original peer-reviewed articles:** 27

3) **First author (total articles):** 35

4) **H-index**: 19

5) **Total citations:** 1018

**Publications (Peer-Reviewed) (from a total of 66)**

1. Antoniou K, **Tzouvelekis A,** Alexandrakis MG, Tsiligianni I, Tzanakis N, Sfiridaki K, Rachiotis G, Bouros D, and Siafakas NM. Perforin down-regulation and adhesion molecules activation in pulmonary sarcoidosis: an induced sputum and BAL study. *Chest* 2006; 129:1592-1598. PMID:16778280
2. Antoniou KM., **Tzouvelekis A,** Alexandrakis MG, K. Sfiridaki K, Tsiligianni I, Rachiotis G, Tzanakis N, Bouros D, Milic-Emili J, and Siafakas NM. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. *Chest* 2006; 130:982-988. PMID:17035428
3. Spagnolo P, Sato H, Renzoni EA, Marshall SE, Wells AU, **Tzouvelekis A,** Grutters JC, Ruven H, van Moorsel C, van den Bosch J, du Bois RM, Welsh KI. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. *Tissue antigens* 2007;70:219-27. PMID:17661910
4. **Tzouvelekis A,** Harokopos V, Paparountas P, Oikonomou N, Hatziioannou A, Karameris A, Tsiambas E, Vilaras G, Bouros D and Aidinis V. Comparative expression profiling and meta-analysis in pulmonary fibrosis suggests an early role of Hypoxia inducible factor 1 in disease pathogenesis. *Am J Respir Crit Care Med* 2007;176(11):1108-19. PMID:17761615
5. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tzouvelekis%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus)**,** [Aidinis V](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Aidinis%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Harokopos V](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Harokopos%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Karameris A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Karameris%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Zacharis G](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Zacharis%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Mikroulis D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mikroulis%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Konstantinou F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Konstantinou%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Steiropoulos P](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Steiropoulos%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Sotiriou I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sotiriou%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Froudarakis M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Froudarakis%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Pneumatikos I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pneumatikos%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Tringidou R](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tringidou%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Bouros D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bouros%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. [*Respir Res.*](javascript:AL_get(this,%20'jour',%20'Respir%20Res.');) 2009;10:14. PMID:19250543; PMCID:PMC2662808
6. [Kotsianidis I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kotsianidis%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Nakou E](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nakou%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Bouchliou I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bouchliou%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tzouvelekis%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus)**,** [Spanoudakis E](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Spanoudakis%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Steiropoulos P](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Steiropoulos%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Sotiriou I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sotiriou%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Aidinis V](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Aidinis%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Margaritis D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Margaritis%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Tsatalas C](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tsatalas%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Bouros D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bouros%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. [*Am J Respir Crit Care Med.*](javascript:AL_get(this,%20'jour',%20'Am%20J%20Respir%20Crit%20Care%20Med.');) 2009;179(12):1121-30. PMID:19342412
7. Oikonomou N, Thanasopoulou A, **Tzouvelekis A,** Harokopos V, Paparountas T, Nikitopoulou I, Witke W, Karameris A, Kotanidou A, Bouros D and Aidinis V. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. [*Thorax*.](javascript:AL_get(this,%20'jour',%20'Thorax.');) 2009;64(6):467-75. PMID:19213772
8. [Pandit KV](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pandit%20KV%22%5BAuthor%5D), [Corcoran D](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Corcoran%20D%22%5BAuthor%5D), [Yousef H](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yousef%20H%22%5BAuthor%5D), [Yarlagadda M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yarlagadda%20M%22%5BAuthor%5D), [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tzouvelekis%20A%22%5BAuthor%5D)**,** [Gibson KF](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gibson%20KF%22%5BAuthor%5D), [Konishi K](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Konishi%20K%22%5BAuthor%5D), [Yousem SA](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yousem%20SA%22%5BAuthor%5D), [Singh M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Singh%20M%22%5BAuthor%5D), [Handley D](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Handley%20D%22%5BAuthor%5D), [Richards T](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Richards%20T%22%5BAuthor%5D), [Selman M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Selman%20M%22%5BAuthor%5D), [Watkins SC](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Watkins%20SC%22%5BAuthor%5D), [Pardo A](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pardo%20A%22%5BAuthor%5D), [Ben-Yehudah A](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ben-Yehudah%20A%22%5BAuthor%5D), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bouros%20D%22%5BAuthor%5D), [Eickelberg O](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Eickelberg%20O%22%5BAuthor%5D), [Ray P](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ray%20P%22%5BAuthor%5D), [Benos PV](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Benos%20PV%22%5BAuthor%5D), [Kaminski N](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kaminski%20N%22%5BAuthor%5D). Inhibition and Role of Let-7d in Idiopathic Pulmonary Fibrosis. [*Am J Respir Crit Care Med.*](javascript:AL_get(this,%20'jour',%20'Am%20J%20Respir%20Crit%20Care%20Med.');) 2010;182 (2):220-9. PMID:20395557; PMCID:PMC2913236
9. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22135741)**,** [Bouros E](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22135741), [Oikonomou A](http://www.ncbi.nlm.nih.gov/pubmed?term=Oikonomou%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22135741), [Ntolios P](http://www.ncbi.nlm.nih.gov/pubmed?term=Ntolios%20P%5BAuthor%5D&cauthor=true&cauthor_uid=22135741), [Zacharis G](http://www.ncbi.nlm.nih.gov/pubmed?term=Zacharis%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22135741), [Kolios G](http://www.ncbi.nlm.nih.gov/pubmed?term=Kolios%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22135741), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22135741). Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. [*Pulm Med.*](http://www.ncbi.nlm.nih.gov/pubmed/22135741) 2011;2011:849035. PMID:22135741; PMCID:PMC3206363
10. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23181555)**,** [Ntolios P](http://www.ncbi.nlm.nih.gov/pubmed?term=Ntolios%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Karameris A](http://www.ncbi.nlm.nih.gov/pubmed?term=Karameris%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Koutsopoulos A](http://www.ncbi.nlm.nih.gov/pubmed?term=Koutsopoulos%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Boglou P](http://www.ncbi.nlm.nih.gov/pubmed?term=Boglou%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Koulelidis A](http://www.ncbi.nlm.nih.gov/pubmed?term=Koulelidis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Archontogeorgis K](http://www.ncbi.nlm.nih.gov/pubmed?term=Archontogeorgis%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Zacharis G](http://www.ncbi.nlm.nih.gov/pubmed?term=Zacharis%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Drakopanagiotakis F](http://www.ncbi.nlm.nih.gov/pubmed?term=Drakopanagiotakis%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Steiropoulos P](http://www.ncbi.nlm.nih.gov/pubmed?term=Steiropoulos%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Anevlavis S](http://www.ncbi.nlm.nih.gov/pubmed?term=Anevlavis%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Polychronopoulos V](http://www.ncbi.nlm.nih.gov/pubmed?term=Polychronopoulos%20V%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Mikroulis D](http://www.ncbi.nlm.nih.gov/pubmed?term=Mikroulis%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23181555), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23181555). Expression of Hypoxia-Inducible Factor (HIF)-1a-Vascular Endothelial Growth Factor (VEGF)-Inhibitory Growth Factor (ING)-4- axis in sarcoidosis patients.[*BMC Res Notes.*](http://www.ncbi.nlm.nih.gov/pubmed/23181555) 2012;5(1):654. PMID:23181555; PMCID:PMC3536569
11. [Oikonomou N](http://www.ncbi.nlm.nih.gov/pubmed?term=Oikonomou%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Mouratis MA](http://www.ncbi.nlm.nih.gov/pubmed?term=Mouratis%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22744859)**,** [Kaffe E](http://www.ncbi.nlm.nih.gov/pubmed?term=Kaffe%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Valavanis C](http://www.ncbi.nlm.nih.gov/pubmed?term=Valavanis%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Vilaras G](http://www.ncbi.nlm.nih.gov/pubmed?term=Vilaras%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Karameris A](http://www.ncbi.nlm.nih.gov/pubmed?term=Karameris%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Prestwich GD](http://www.ncbi.nlm.nih.gov/pubmed?term=Prestwich%20GD%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Aidinis V](http://www.ncbi.nlm.nih.gov/pubmed?term=Aidinis%20V%5BAuthor%5D&cauthor=true&cauthor_uid=22744859). Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. [*Am J Respir Cell Mol Biol.*](http://www.ncbi.nlm.nih.gov/pubmed/22744859) 2012;47(5):566-74. PMID:22744859
12. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23697753)**,** [Zacharis G](http://www.ncbi.nlm.nih.gov/pubmed?term=Zacharis%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Oikonomou A](http://www.ncbi.nlm.nih.gov/pubmed?term=Oikonomou%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Mikroulis D](http://www.ncbi.nlm.nih.gov/pubmed?term=Mikroulis%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Margaritopoulos G](http://www.ncbi.nlm.nih.gov/pubmed?term=Margaritopoulos%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Koutsopoulos A](http://www.ncbi.nlm.nih.gov/pubmed?term=Koutsopoulos%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Antoniadis A](http://www.ncbi.nlm.nih.gov/pubmed?term=Antoniadis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Koulelidis A](http://www.ncbi.nlm.nih.gov/pubmed?term=Koulelidis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Steiropoulos P](http://www.ncbi.nlm.nih.gov/pubmed?term=Steiropoulos%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Boglou P](http://www.ncbi.nlm.nih.gov/pubmed?term=Boglou%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Bakali M](http://www.ncbi.nlm.nih.gov/pubmed?term=Bakali%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Froudarakis M](http://www.ncbi.nlm.nih.gov/pubmed?term=Froudarakis%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23697753), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23697753). Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema*.* [*BMC Pulm Med.*](http://www.ncbi.nlm.nih.gov/pubmed/23697753) 2013;13(1):31. PMID:23697753; PMCID:PMC3667148
13. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653)**,** [Paspaliaris V](http://www.ncbi.nlm.nih.gov/pubmed?term=Paspaliaris%20V%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Koliakos G](http://www.ncbi.nlm.nih.gov/pubmed?term=Koliakos%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Ntolios P](http://www.ncbi.nlm.nih.gov/pubmed?term=Ntolios%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Bouros E](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Oikonomou A](http://www.ncbi.nlm.nih.gov/pubmed?term=Oikonomou%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Zissimopoulos A](http://www.ncbi.nlm.nih.gov/pubmed?term=Zissimopoulos%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Boussios N](http://www.ncbi.nlm.nih.gov/pubmed?term=Boussios%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Dardzinski B](http://www.ncbi.nlm.nih.gov/pubmed?term=Dardzinski%20B%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Gritzalis D](http://www.ncbi.nlm.nih.gov/pubmed?term=Gritzalis%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Antoniadis A](http://www.ncbi.nlm.nih.gov/pubmed?term=Antoniadis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Froudarakis M](http://www.ncbi.nlm.nih.gov/pubmed?term=Froudarakis%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Kolios G](http://www.ncbi.nlm.nih.gov/pubmed?term=Kolios%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23855653). A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. [*J Transl Med*.](http://www.ncbi.nlm.nih.gov/pubmed/23855653) 2013 ;11(1):171. PMID:23855653; PMCID:PMC3722100
14. **Tzouvelekis A,** Bouros D. Anti-acid treatment for idiopathic pulmonary fibrosis. *Lancet Respir Med*. 2013 Jul;1(5):348-9. PMID:24429187
15. Bouros D, **Tzouvelekis A.** Idiopathic Pulmonary Fibrosis: On the move. *Lancet Respir Med.* 2014;2(1):17-9. PMID:24461889

**D. Research Support**

**Ongoing Research Support**

UH2 HL123886-01 (Kaminski) 7/1/14 – 6/30/19

NIH / NHLBI

**Mir-29 Mimicry as a Therapy for Pulmonary Fibrosis**

The overall objective of this proposal is to develop miR-29 mimicry as a long-term, efficient and personalized anti-fibrotic therapy. The rationale for this proposal stems from the significant body of work that indicates the important anti-fibrotic role of miR-29 in fibrosis, the efficacy of the mirage miR-29 mimic and the likelihood of identifying a high risk IPF patient population likely to benefit from miR-29 supplementation.

Role: Postdoctoral Associate

Biogen Idec, Inc (Kaminski) 7/1/14 – 6/30/16

**Molecular Phenotyping of Disease Relevant Cell Populations in IPF**

The focus of this research project is to carry out molecular phenotyping of disease relevant cell populations in IPF lungs.

Role: Postdoctoral Associate

U01 (Benos / University of Pittsburgh) 7/1/14 – 6/30/18

NIH / NHLBI

**Center for Casual Modeling and Discovery of Biomedical Knowledge from Big Data**

In this grant, we propose to capitalize on the publicly available and private data from the Lung Genomics Research Consortium (LGRC) and Lung Tissue Research Consortium (LTRC) resources to develop the software and tools to identify causal relationships between (1) omic data and image features and (2) disease characteristics and subtypes

Role: Postdoctoral Associate

Senior Research Training Fellowship/Proposal No: RT-350419 7/1/2015 – 7//12016

American Lung Association

**SHP-2 as a Novel Anti-Fibrotic Agent in IPF**

The overall objective is to understand the mechanisms of SHP-2 action within the fibrotic lung and determine whether SHP-2 could serve as a therapeutic target in IPF.

Role: Senior Post-Doc

ERS/Marie Skłodowska-Curie Postdoctoral Research Fellowship 30/4/2016 – 30/4/2018

RESPIRE2 3rd round/Proposal No: 8860-2015

**The role of phosphatases as anti-fibrotic regulators of fibroblast homeostasis in pulmonary fibrosis**

The overall objective is to understand the mechanisms of SHP-2 action within the fibrotic lung and determine whether SHP-2 could serve as a therapeutic target in IPF.

Role: Senior Post-Doc

**Pending Research Support**

None

**Completed Research Support (last 3 years)**

Hellenic Thoracic Society (Tzouvelekis) 11/1/2011 – 11/1/2013

Unrestricted Research Grant

**Study of the role of the adipose derived stem cells-stromal vascular fraction (SVF) in the treatment and pathogenesis of lung fibrosis**

Goals: Study the effects of three endobronchial infusions of autologous adipose-derived stem cells-stromal vascular fraction in patients with mild-to-moderate Idiopathic Pulmonary Fibrosis in the context of a non-randomized no placebo-controlled phase Ib clinical trial in 1) incidence of treatment emergent adverse events (safety-primary end-point), 2) functional, exercise capacity and quality of life parameters (efficacy-secondary end-points)

Role: PI

The Godrej Group, India (Tzouvelekis) 9/1/2011 – 9/1/2013

Unrestricted Research Grant

**Study of the role of the adipose derived stem cells-stromal vascular fraction (SVF) in the treatment and pathogenesis of lung fibrosis**

Goals: Study the effects of three endobronchial infusions of autologous adipose-derived stem cells-stromal vascular fraction in patients with mild-to-moderate Idiopathic Pulmonary Fibrosis in the context of a non-randomized no placebo-controlled phase Ib clinical trial in 1) incidence of treatment emergent adverse events (safety-primary end-point), 2) functional, exercise capacity and quality of life parameters (efficacy-secondary end-points)

Role: PI

**E. Member of Scientific Societies:** Hellenic Thoracic, European Respiratory and American Thoracic Society